Literature DB >> 27591406

The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography.

M Pardini1, D Botzkowski2, S Müller3, J Vehoff3, J Kuhle4,5, E Ruberte6, J Würfel6, A Gass7, C Valmaggia8, B Tettenborn3, N Putzki2, Ö Yaldizli4.   

Abstract

BACKGROUND AND
PURPOSE: N-acetyl aspartate (NAA) assessed using proton magnetic resonance spectroscopy (1 H MRS) has a high pathological specificity for axonal density. Retinal nerve fibre layer thickness (RNFLT) measured by using optical coherence tomography is increasingly used as a surrogate marker of neurodegeneration in multiple sclerosis (MS). Our aim was to investigate the relation between RNFLT and NAA/creatine in brain normal-appearing white matter (NAWM), their dynamics over time and the association with clinical outcome measures in relapsing MS. T2 WM lesions served as control tissue.
METHODS: Forty-three MS patients underwent standardized neurological examination including the Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC) score, optical coherence tomography and magnetic resonance imaging including 1 H MRS at baseline and after 1 year.
RESULTS: At baseline, NAA/creatine level was lower in T2 WM lesions than in NAWM (1.64 ± 0.16 vs. 1.88 ± 0.24, P < 0.001). Lowest levels were found in secondary progressive MS (SPMS). Mean RNFLT was higher in clinically isolated syndrome than in the combined group of relapsing-remitting MS and SPMS (99.8 ± 12.3 μm vs. 92.4 ± 12.8 μm, P = 0.038). In all patients, mean RNFLT decreased by 1.4% during follow-up. At baseline, MSFC z-scores correlated with NAA/creatine levels both in NAWM (r = 0.42; P = 0.008) and T2 WM lesions (r = 0.52, P = 0.004). NAWM NAA/creatine variation correlated with the RNFLT change over 1 year (ρ = 0.43, P = 0.046).
CONCLUSIONS: N-acetyl aspartate/creatine level reduction correlated with RNFLT thinning over 1 year in an EDSS stable MS cohort suggesting that these techniques might be sensitive to detect subclinical disease progression.
© 2016 EAN.

Entities:  

Keywords:  N-acetyl aspartate; magnetic resonance spectroscopy; multiple sclerosis; optical coherence tomography; retinal nerve fibre layer thickness

Mesh:

Substances:

Year:  2016        PMID: 27591406     DOI: 10.1111/ene.13116

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  4 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 2.  Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.

Authors:  Maria Pia Sormani; Matteo Pardini
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 3.  Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker.

Authors:  Kelley M Swanberg; Karl Landheer; David Pitt; Christoph Juchem
Journal:  Front Neurol       Date:  2019-11-15       Impact factor: 4.003

4.  Circulating N-Acetylaspartate does not track brain NAA concentrations, cognitive function or features of small vessel disease in humans.

Authors:  Eleni Rebelos; Giuseppe Daniele; Beatrice Campi; Alessandro Saba; Kalle Koskensalo; Jukka Ihalainen; Ekaterina Saukko; Pirjo Nuutila; Walter H Backes; Jacobus F A Jansen; Pieter C Dagnelie; Sebastian Köhler; Bastiaan E de Galan; Thomas T van Sloten; Coen D A Stehouwer; Ele Ferrannini
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.